Key facts
- Levron Cardiovascular’s last known valuation is $1.8M (Aug 2025).
- It has raised $870K; the latest was Early Stage VC ($870K) in Aug 2025.
- Notable investors include Alon MedTech Ventures, Shoni Health Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Levron Cardiovascular
- ·The full record, as it builds
Funding rounds
No funding rounds for Levron Cardiovascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Levron Cardiovascular
Developer of a novel autonomic integrated diagnostic and therapeutic invasive device designed to treat heart failure patients. The company specializes in adaptive treatment for NYHA stage three heart failure eliminating lung congestion, preventing cardiac decompensation, enabling industries with a device that integrates diagnosis and treatment shifts fluids from the lung, and reduces the cardiac workloads.
- Sector
- Healthcare
- HQ
- Yokneam, Israel
- Founded
- 2021
- Employees
- 5
- Website
- levron-medical.com/
- Ownership
- Privately Held (backing)
Levron Cardiovascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Levron Cardiovascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Levron Cardiovascular in its N-PORT filings yet. We sweep new filings monthly.